# Molecular-informed image classification for predicting drug sensitivity in cancer therapy

## TL;DR

This paper introduces a new imaging framework that improves drug sensitivity predictions in cancer by integrating molecular data with adaptive image analysis.

## Contribution

The novel DSINet and PSGO strategy dynamically adapt to molecular content and enhance robustness in biological imaging.

## Key findings

- DSINet outperforms existing methods in classifying molecular patterns linked to drug sensitivity.
- PSGO improves reconstruction by focusing on high-confidence regions and restructuring feature graphs.
- The approach offers a reliable foundation for personalized cancer therapy strategies.

## Abstract

Understanding and predicting drug sensitivity in cancer therapy demands innovative approaches that integrate multi-modal data to enhance treatment efficacy. In alignment with the advancing scope of precision oncology and the molecularly informed therapeutic decision-making emphasized by contemporary cancer research, this work proposes a dynamic and structure-aware imaging framework for robust molecular-informed image classification. Traditional methodologies often suffer from rigid modeling assumptions and inadequate handling of complex, heterogeneous noise prevalent in biological imaging, which limits their predictive accuracy and generalizability.

To address these challenges, we introduce a novel dynamic structure-aware imaging network (DSINet) coupled with a progressive structure-guided optimization (PSGO) strategy. DSINet dynamically adapts spatial filters based on local molecular content, preserves critical biological structures through attention mechanisms, and incorporates uncertainty-aware fusion across multiple resolutions. PSGO further refines the reconstruction by progressively focusing optimization on high-confidence regions and adaptively restructuring feature graphs to enhance robustness against variable imaging artifacts.

Extensive experimental evaluations demonstrate that our method significantly outperforms techniques in classifying molecular patterns correlated with drug sensitivity, offering a reliable and interpretable foundation for advancing personalized cancer therapy strategies. This approach seamlessly integrates cutting-edge adaptive imaging models with the emerging needs of molecular-insight-driven therapeutic optimization, bridging critical gaps in current cancer informatics research.